BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed SUPN catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:79fe13acb117a5bfac06@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:SUPN P3 readout (est.): Open-label Study to Evaluate Long-term Safe
 ty and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)
DESCRIPTION:Open-label Study to Evaluate Long-term Safety and Efficacy of S
 PN-812 (Viloxazine Extended-release Capsule)\nNCT02736656 | PHASE3 | ACTIV
 E_NOT_RECRUITING | sponsor: Supernus Pharmaceuticals\, Inc.\nPrimary compl
 etion date (ESTIMATED)\; top-line results usually follow later.\nDate prec
 ision: month (shown on the first day)\nTicker SUPN (confidence 0.9)\nSourc
 e: https://clinicaltrials.gov/study/NCT02736656\nScheduling/reference data
  from public records\; dates can move. Not investment\, legal or medical a
 dvice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT02736656
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:fb53bcf1084afcf1336c@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:SUPN P1/P2 readout (est.): FIAS
DESCRIPTION:BIS-001-ER for the Treatment of Adult Focal Impaired Awareness 
 Seizures\nNCT03474770 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: S
 upernus Pharmaceuticals\, Inc.\nPrimary completion date (ESTIMATED)\; top-
 line results usually follow later.\nTicker SUPN (confidence 0.9)\nSource: 
 https://clinicaltrials.gov/study/NCT03474770\nScheduling/reference data fr
 om public records\; dates can move. Not investment\, legal or medical advi
 ce.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT03474770
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:279e2b5bfa3e39923e37@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:SUPN P2 readout (est.): Double-blind\, Placebo-controlled Study in 
 Adults With Major Depressive Disorder
DESCRIPTION:Double-blind\, Placebo-controlled Study in Adults With Major De
 pressive Disorder\nNCT07226661 | PHASE2 | RECRUITING | sponsor: Supernus P
 harmaceuticals\, Inc.\nPrimary completion date (ESTIMATED)\; top-line resu
 lts usually follow later.\nTicker SUPN (confidence 0.9)\nSource: https://c
 linicaltrials.gov/study/NCT07226661\nScheduling/reference data from public
  records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07226661
CATEGORIES:readout,ESTIMATED
END:VEVENT
END:VCALENDAR
